AlphAIAlphAI — Financial news for AI agents
rttnews.com$ANGO

AngioDynamics Reiterates FY27 Outlook; Appoints Eric Honroth President And CEO - Update

AngioDynamics (ANGO) reported Q1 results and reiterated its FY27 adjusted loss guidance of $0.29-$0.24 per share and net sales guidance of $336M-$341M. The company expects tariff impacts similar to FY26. Eric Honroth will become CEO on November 2, 2026, succeeding Jim Clemmer. ANGO stock is up 0.42% in pre-market trading.

Original reporting
rttnews.com
Published Oct 8, 2026, 11:36 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 1:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ANGO
Neutral
high confidence
Mentioned
$ANGO
Relevance
7/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$ANGONeutralMed
01

Why it matters

The reaffirmed guidance suggests earnings stability, while the leadership change may reduce execution risk, supporting a modest bullish stance.

02

Market read

First report of FY27 guidance and CEO appointment provides actionable insight for traders focusing on small‑cap medical device stocks.

03

What to watch

Potential tariff impacts and execution of the new CEO's strategy could affect future performance.

Relevance 7/10Novelty 7/10Timing: pre-market today

Background

AngioDynamics (NASDAQ: ANGO) reported Q1 results, reaffirmed FY27 guidance, and named Eric Honroth as President and CEO.

Company-level read

Ticker impact

$ANGONeutralHigh confidence
Context

AngioDynamics reiterated FY27 adjusted loss guidance and announced a new CEO, providing fresh guidance numbers and leadership change.

Expected impact

likely modest upside as market prices in stable guidance and leadership continuity

Evidence & confidence

The guidance range is unchanged, but the CEO appointment reduces uncertainty, prompting modest buying pressure.

Market effects

Sector

Stable guidance may reinforce expectations for the medical device sector's earnings outlook.

Regional

Limited to U.S. small‑cap medical device investors.

Global

Minimal global impact beyond sector peers.

Counterpoint

What could challenge this read

Investors could view unchanged guidance as a lack of growth momentum and short the stock.

Key entities

  • Company
    AngioDynamics, Inc.

    Medical device manufacturer reporting Q1 and FY27 outlook.

  • Executive
    Eric Honroth

    New President and CEO effective Nov 2, 2026.

Read at source← All news

StoryAngioDynamics posts Q1 FY2027 earnings beat and names new CEO

Also covered by

4 outlets

Related articles

$ANGOMed

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife IRE for Prostate and Liver Cancer

AngioDynamics announced that Humana updated its Medicare Advantage coverage policy to include NanoKnife IRE for prostate and liver cancer, effective October 1, 2026. This follows recent reimbursement milestones, including new CPT codes and Palmetto GBA's LCD L40205. Humana, with 7 million members, will use LCD L40205 criteria for coverage, subject to prior authorization.

marketscreener.com
$ANGOMed

H.C. Wainwright cuts AngioDynamics stock price target to $18

H.C. Wainwright reduced its price target for AngioDynamics (ANGO) to $18 from $19, maintaining a Buy rating. The company reported fiscal Q1 2027 net sales of $80.9M, up 6.9% YoY, but a net loss of $7.1M. Guidance for fiscal 2027 includes revenue of $336M-$341M and adjusted EBITDA of $13M-$16M. Canaccord Genuity reiterated its Buy rating with a $20 target, citing growth in key platforms. The stock fell 23% post-earnings.

investing.com
$ANGOMed

AngioDynamics Announces Humana Medicare Advantage Coverage Polic

AngioDynamics (ANGO) announced Humana's updated Medicare Advantage coverage policy for its NanoKnife System, effective October 1, 2026. The policy applies LCD L40205 criteria for IRE technology, covering eligible patients with intermediate-risk prostate cancer and certain liver tumors. This follows recent reimbursement milestones, including CPT codes and Palmetto GBA's LCD. Humana, with 7 million members, will use LCD L40205 criteria for consistent coverage.

gurufocus.com
$ANGOHigh

AngioDynamics (ANGO) Q1 2027 Earnings Call Transcript

AngioDynamics (ANGO) reported Q1 2027 revenue growth of 7%, with the MedTech segment up 13%. Auryon saw 14.7% growth, marking 21 consecutive quarters of double-digit gains. AlphaVac revenue rose 37.4% year-over-year. The company named Eric Honer as its new CEO, effective November 2. NanoKnife received FDA approval for a BPH study, targeting a $1.9B market. Med Device segment grew 1.4%.

finance.yahoo.com